1. Home
  2. REFI vs PROC Comparison

REFI vs PROC Comparison

Compare REFI & PROC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • REFI
  • PROC
  • Stock Information
  • Founded
  • REFI 2021
  • PROC 1976
  • Country
  • REFI United States
  • PROC Luxembourg
  • Employees
  • REFI N/A
  • PROC N/A
  • Industry
  • REFI Real Estate Investment Trusts
  • PROC Biotechnology: Pharmaceutical Preparations
  • Sector
  • REFI Real Estate
  • PROC Health Care
  • Exchange
  • REFI Nasdaq
  • PROC Nasdaq
  • Market Cap
  • REFI 298.7M
  • PROC 283.2M
  • IPO Year
  • REFI 2021
  • PROC N/A
  • Fundamental
  • Price
  • REFI $16.00
  • PROC $2.51
  • Analyst Decision
  • REFI Buy
  • PROC Hold
  • Analyst Count
  • REFI 4
  • PROC 1
  • Target Price
  • REFI $17.33
  • PROC $4.50
  • AVG Volume (30 Days)
  • REFI 112.0K
  • PROC 3.7K
  • Earning Date
  • REFI 08-07-2024
  • PROC 09-03-2024
  • Dividend Yield
  • REFI 11.76%
  • PROC N/A
  • EPS Growth
  • REFI 0.51
  • PROC N/A
  • EPS
  • REFI 1.99
  • PROC 0.52
  • Revenue
  • REFI $55,477,705.00
  • PROC $414,096,000.00
  • Revenue This Year
  • REFI $15.73
  • PROC $5.54
  • Revenue Next Year
  • REFI $7.11
  • PROC $8.54
  • P/E Ratio
  • REFI $7.96
  • PROC $4.83
  • Revenue Growth
  • REFI 2.73
  • PROC N/A
  • 52 Week Low
  • REFI $13.86
  • PROC $1.95
  • 52 Week High
  • REFI $17.65
  • PROC $4.95
  • Technical
  • Relative Strength Index (RSI)
  • REFI 63.34
  • PROC 44.80
  • Support Level
  • REFI $15.17
  • PROC $2.49
  • Resistance Level
  • REFI $15.83
  • PROC $2.81
  • Average True Range (ATR)
  • REFI 0.26
  • PROC 0.08
  • MACD
  • REFI 0.06
  • PROC 0.01
  • Stochastic Oscillator
  • REFI 100.00
  • PROC 6.23

About REFI Chicago Atlantic Real Estate Finance Inc.

Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.

About PROC Procaps Group S.A.

Procaps Group SA is a developer of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies. It develops, manufactures, and markets over-the-counter (OTC) and prescription drugs, nutritional supplements, and high-potency clinical solutions. The company's segment includes NextGel; Procaps Colombia; CAN; CASAND and Diabetrics. It generates maximum revenue from the Procaps Colombia segment.

Share on Social Networks: